NCT01086553已完成3 期
Double-blind, Double-dummy, Randomised, Comparative, Multi-centre Phase III Study on the Efficacy and Tolerability of an 8-week Oral Treatment With 9 mg Budesonide Once Daily vs. 3 mg Budesonide Three-times Daily in Patients With Active Crohn's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 471
- 试验地点
- 1
- 主要终点
- Rate of clinical remission, defined as a CDAI < 150, at week 8 (LOCF)
研究概览
简要总结
This study aims to evaluate the efficacy of 9 mg budesonide once daily (OD) versus 3 mg budesonide three-times daily (TID) for the induction of remission in Crohn's disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent,
- •Age 18 to 75 years,
- •Symptoms of Crohn's disease since at least 3 months; diagnosis confirmed by endoscopic and histological, or endoscopic and radiological criteria [endoscopy not older than 12 months or if older, then clinical signs (e.g., pain localisation, pain intensity, blood in stool) and behaviour (according to Montreal classification) should be unchanged compared to former episodes],
- •Localisation of CD either in terminal ileum, coecum, ascending colon, or ileocolitis,
- •Active phase of disease (200 < CDAI < 400),
- •Negative pregnancy test in females of childbearing potential,
- •Women of child-bearing potential have to apply appropriate contraceptive methods, e.g., hormonal contraception, intrauterine device (IUD), double-barrier method of contraception (e.g., use of a condom and spermicide), or partner has undergone vasectomy. The investigator is responsible for determining whether the subject has adequate birth control for study participation.
排除标准
- •Known Crohn's lesions in the upper GI-tract (up to and including the jejunum) or rectum with present symptoms,
- •Septic complications,
- •Evidence of infectious diarrhoea (i.e., pathogenic bacteria in stool culture),
- •Abscess, perforation, or active fistulas,
- •Ileostomy or colostomy,
- •Resection of more than 50 cm of the ileum,
- •Bowel surgery within the last 3 months,
- •Immediate surgery required (e.g., major stenosis, serious bleeding, peritonitis, ileus),
- •Clinical signs of stricturing disease,
- •Subileus within the last 6 months (subileus with inflammatory hint allowed),
- •Suspicion of ileus, subileus or corresponding symptoms,
- •Parenteral or tube feeding,
- •Active peptic ulcer disease, local intestinal infection, or known established cataract,
- •Diabetes mellitus, infection, osteoporosis, glaucoma, tuberculosis, or hypertension if careful medical monitoring is not ensured,
- •Abnormal hepatic function (ALT or ALP > 2.5 x upper limit of normal [ULN]), liver cirrhosis, or portal hypertension,
- •Abnormal renal function (Cystatin C > ULN),
- •Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder,
- •History of cancer in the last five years (except for non-metastatic cancers, e.g., basalioma),
- •Treatment with immunosuppressants or anti-cancer drugs, e.g., 6 TG, methotrexate, tacrolimus, cyclophosphamide, or cyclosporine within the last 3 months; in case of treatment with azathioprine or 6 MP the drugs have to be used for maintenance of remission only and dosage has to be unchanged within the last 3 months before baseline visit and during the study,
- •Treatment with ketoconazole or other CYP3A inhibitors within the last month before baseline visit,
- •Treatment with anti-TNF-alpha therapy within 3 months before baseline visit,
- •Conventional steroids (iv, po, rectal) within 2 weeks before baseline visit,
- •> 6 mg/d budesonide po within 2 weeks before baseline visit,
- •Steroids for inhalation within 2 weeks before baseline visit,
- •Patients known to be steroid-refractory,
- •Treatment of study disease with oral antibiotics (e.g., metronidazole or ciprofloxacin) within the last 2 weeks,
- •Application of non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks before baseline visit except ≤ 350 mg/d or short-term acetylsalicylic acid (paracetamol is allowed),
- •Known intolerance/hypersensitivity to study drug,
- •Well-founded doubt about the patient's cooperation, e.g., because of addiction to alcohol or drugs,
- •Existing or intended pregnancy or breast-feeding,
- •Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial.
研究组 & 干预措施
A
Experimental
9mg budesonide OD
干预措施: budesonide (Drug)
B
Active Comparator
3mg budesonide TID
干预措施: budesonide (Drug)
结局指标
主要结局
Rate of clinical remission, defined as a CDAI < 150, at week 8 (LOCF)
时间窗: 8 weeks
次要结局
- Response to treatment defined as CDAI < 150 or CDAI reduction of > 100 points(8 weeks)
- Adverse events(8 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)Oral Chronic Graft vs Host DiseaseNCT00887263Dr. Falk Pharma GmbH186
已完成
2 期
Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of ARSeasonal Allergic RhinitisNCT00938613Ligand Pharmaceuticals65
已完成
3 期
Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)Ulcerative ColitisNCT01532648Bausch Health Americas, Inc.510
已完成
3 期
Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)Colitis, UlcerativeNCT00747110Dr. Falk Pharma GmbH343
已完成
3 期
SOIBD Collagenous Colitis Maintenance StudyInduction and Maintaining Remission of Collagenous ColitisNCT01278082Dr. Falk Pharma GmbH92